Scienture (NASDAQ:SCNX – Get Free Report) released its earnings results on Friday. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.15, FiscalAI reports. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.40 million.
Scienture Stock Performance
Shares of NASDAQ:SCNX traded down $0.01 on Friday, hitting $0.40. 202,409 shares of the company were exchanged, compared to its average volume of 2,380,695. The company’s 50 day moving average price is $0.40 and its two-hundred day moving average price is $0.50. Scienture has a one year low of $0.24 and a one year high of $2.60. The firm has a market capitalization of $16.37 million, a price-to-earnings ratio of -0.15 and a beta of 3.32.
Analyst Upgrades and Downgrades
A number of research firms have weighed in on SCNX. Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a research report on Friday, March 27th. Maxim Group began coverage on shares of Scienture in a research report on Tuesday, February 24th. They set a “buy” rating and a $1.50 target price for the company. Finally, Wall Street Zen raised shares of Scienture to a “hold” rating in a research report on Saturday, March 14th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $1.50.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Scienture stock. Geode Capital Management LLC raised its stake in shares of Scienture Holdings, Inc. (NASDAQ:SCNX – Free Report) by 264.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 316,201 shares of the company’s stock after purchasing an additional 229,398 shares during the quarter. Geode Capital Management LLC owned 0.78% of Scienture worth $161,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 5.68% of the company’s stock.
Scienture Company Profile
Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
Featured Articles
- Five stocks we like better than Scienture
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
